| ID | 1052 |
| Name of the vaccine | Shan-5 |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | From 6 weeks |
| Description of the vaccine | Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae type b conjugate vaccine. |
| Name of the manufacturer | Sanofi Healthcare India Private Limited |
| Name of the manufacturing country | India |
| Year of manufacture | 2014 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | Seroprotection rate of 70.1% for whole cell Pertussis. |
| Vaccine formulation | White suspension |
| Dosage | Three doses of 0.5 ml, at least 4 weeks gap. |
| Mechanism of action | Boosts the immune system and produces protective antibodies. |
| Route of administration | Intramuscular |
| Indications | Immunization against diphtheria, tetanus, pertussis, hepatitis B and haemophilus influenzae type b in infants. |
| Export | Marketed by : Sanofi Healthcare India Private Limited |
| Approval | Central Drugs Standard Control Organization, India and WHO pre-qualified. |
| Adjuvant | Aluminium phosphate |
| Repurposing | For diphtheria, Hib, tetanus and hepatitis B. |
| Side effects of vaccine | Pain, redness and swelling at injection site, fever, vomiting, crying, drowsiness, loss of appetite and irritability. |
| Post vaccination | Vaccinee to be medically supervised for at least 30 minutes after vaccination. |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://extranet.who.int/pqweb/content/shan-5-0 |
| Other name | NA |
| Additional Links | https://www.1mg.com/drugs/shan-5-vaccine-264976
|